CW February 2004
Volume 13Issue Number 2 February 2004 ISSN 10593802 Anastrozole Advantages Warrant Switch in Early Breast CancerDisease recurrence risks and adverse events are lower when postmenopausal women with early breast cancer are switched from tamoxifen to the aromatase inhibitor anastrozole (Arimidex, AstraZeneca).
Go to Previous Page Go to Next Page Source & Addtional Reading F. Boccardo, 26th Annual San Antonio Breast Cancer Symposium. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
